Tanvex BioPharma Reports the US FDA’s Approval of Nypozi (Biosimilar, Neupogen)
Shots:
- The US FDA has granted BLA approval of Nypozi (TX01), biosimilar version of Amgen’s Neupogen
- Nypozi (TX01) is intended to reduce the incidence of infection among patients having non-myeloid malignancies undergoing chemotherapy that may reduce neutrophil count
- The company’s Nypozi was introduced across Canada in Jan 2024
Ref: Tanvex | Image: Tanvex
Related News:- Coherus Reports the Divestment of Yusimry (Biosimilar, Humira) to Hong Kong King-Friend Industry
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
